Decentralized Clinical Trials in Early Drug Development—A Framework Proposal by Diogo J. Silva, Blessie Elizabeth Nelson, Jordi Rodon

Get full text

On target methods to induce abscopal phenomenon for Off‐Target effects: From happenstance to happenings by Blessie Elizabeth Nelson, Jacob J. Adashek, Steven H. Lin, Vivek Subbiah

Get full text

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma by Blessie Elizabeth Nelson, Neha K. Reddy, Jason T. Huse, Behrang Amini, Mirella Nardo, Mohamed Gouda, Shiao-Pei Weathers, Vivek Subbiah

Get full text

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study by Blessie Elizabeth Nelson, Jason Roszik, Filip Janku, David S. Hong, Shumei Kato, Aung Naing, Sarina Piha-Paul, Siqing Fu, Apostolia Tsimberidou, Maria Cabanillas, Naifa Lamki Busaidy, Milind Javle, Lauren Averett Byers, John V. Heymach, Funda Meric-Bernstam, Vivek Subbiah

Get full text

RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE study by Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell, Amber M Johnson, Sarina A. Piha-Paul, Isabella C. Glitza Oliva, Shiao-Pei Weathers, Maria Cabanillas, Milind Javle, Funda Meric-Bernstam, Vivek Subbiah

Get full text